Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05673083 · ClinicalTrials.gov registry record
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
A clinical trial of Multiple Myeloma and Multiple Myeloma in Relapse, sponsored by All4Cure.
- Active
- Registry status
- 200
- Enrollment target
- 7
- Study locations
NCT05673083: Active study of Multiple Myeloma and Multiple Myeloma in Relapse, sponsored by All4Cure.
NCT05673083 is a study of Multiple Myeloma and Multiple Myeloma in Relapse that is active but no longer recruiting, run by All4Cure. The registered enrollment target is 200 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (63% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05673083, a study of Multiple Myeloma and Multiple Myeloma in Relapse, is active but no longer recruiting, sponsored by All4Cure.
- ACTIVE NOT RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 7
- Study locations
Study Summary
The goal of this pilot study is to evaluate the impact of All4Cure enrollment on patients with multiple myeloma. The main question it aims to answer are: • Does All4Cure effect patient activation as assessed by the PAM-13 survey? Participants will be asked to: * fill out quarterly PAM-13 surveys through the All4Cure website to assess patient activation. * fill out monthly Patient Reported Outcome (PRO) surveys through the All4Cure website. * fill out a baseline and exit All4Cure surveys through the All4Cure website to assess patient perceptions of All4Cure at the beginning and the end of the study.
Primary Outcome
Patient activation emphasizes patients' willingness and ability to take independent actions to manage their health and care. A widely used definition equates patient activation with understanding one's role in the care process and having the knowledge, skill, and confidence to manage one's health and health care. A growing body of evidence shows that patients who are more activated have better health outcomes and care experiences. This will be assessed through the PAM-13 survey which has a scale
Conditions Studied
Study Locations (7)
Arkansas
- Highlands Oncology Group - Fayetteville
Florida
- Cancer Specialists of North Florida - Jacksonville
Iowa
- Misson Cancer + Blood - Des Moines
New York
- Hematology-Oncology Associates of Central New York - East Syracuse
Oklahoma
- Oklahoma Cancer Specialists and Research Institute - Tulsa
Texas
- Oncology Consultants - Houston
Washington
- Northwest Medical Specialties PLLC - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2026-03 |
What the registry record for NCT05673083 still lists
NCT05673083 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (63% lower).
The record links to 4 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.
NCT05673083 lists 7 locations in 7 states (Arkansas, Florida, Iowa).
Frequently Asked Questions
What is clinical trial NCT05673083 about?
NCT05673083 is a clinical study titled "Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma". The goal of this pilot study is to evaluate the impact of All4Cure enrollment on patients with multiple myeloma. The main question it aims to answer are: • Does All4Cure effect patient activation as assessed by the PAM-13 survey? Participants will be asked to: * fill out quarterly PAM-13 surveys ...
What is the current status of trial NCT05673083?
This trial is currently active not recruiting. The enrollment target is 200 participants. The study started on 2023-03-01. Estimated completion is 2026-03.
What conditions does trial NCT05673083 study?
This clinical trial studies the following conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Multiple Myeloma With Failed Remission.
Who is sponsoring clinical trial NCT05673083?
This trial is sponsored by All4Cure, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05673083 being conducted?
This trial has 7 study locations across Arkansas, Florida, Iowa, New York, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05673083's enrollment target sits among peer trials
200 110th of 438 higher than 324 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI